Orbimed Advisors LLC reduced its holdings in Audentes Therapeutics Inc (NASDAQ:BOLD) by 14.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,129,638 shares of the biotechnology company’s stock after selling 672,000 shares during the quarter. Orbimed Advisors LLC owned about 14.87% of Audentes Therapeutics worth $115,671,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in shares of Audentes Therapeutics in the 3rd quarter valued at approximately $143,000. Nationwide Fund Advisors lifted its holdings in shares of Audentes Therapeutics by 288.9% in the 2nd quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after buying an additional 6,384 shares during the period. Trexquant Investment LP acquired a new stake in shares of Audentes Therapeutics in the 3rd quarter valued at approximately $295,000. State of Wisconsin Investment Board acquired a new stake in shares of Audentes Therapeutics in the 2nd quarter valued at approximately $210,000. Finally, Rhumbline Advisers acquired a new stake in shares of Audentes Therapeutics in the 2nd quarter valued at approximately $252,000. 78.99% of the stock is owned by institutional investors and hedge funds.
Audentes Therapeutics Inc (BOLD) opened at $29.13 on Friday. Audentes Therapeutics Inc has a one year low of $13.90 and a one year high of $33.43.
Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share for the quarter, meeting the consensus estimate of ($0.88). sell-side analysts expect that Audentes Therapeutics Inc will post -3.52 EPS for the current fiscal year.
BOLD has been the subject of several recent analyst reports. Zacks Investment Research cut Audentes Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Evercore ISI assumed coverage on Audentes Therapeutics in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $23.00 price objective for the company. ValuEngine raised Audentes Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 24th. Bank of America reaffirmed a “buy” rating and issued a $33.00 price objective (up from $23.00) on shares of Audentes Therapeutics in a research note on Friday, September 22nd. Finally, Raymond James Financial assumed coverage on Audentes Therapeutics in a research note on Thursday, October 12th. They issued a “market perform” rating for the company. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. Audentes Therapeutics currently has an average rating of “Hold” and a consensus price target of $28.29.
In related news, VP Suyash Prasad sold 8,000 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $28.53, for a total value of $228,240.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Matthew R. Patterson sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $25.06, for a total value of $250,600.00. Following the completion of the transaction, the chief executive officer now directly owns 1,542 shares of the company’s stock, valued at $38,642.52. The disclosure for this sale can be found here. Insiders sold a total of 761,500 shares of company stock valued at $21,457,100 over the last ninety days. 47.30% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Audentes Therapeutics Inc (BOLD) Stake Lowered by Orbimed Advisors LLC” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/10/audentes-therapeutics-inc-bold-stake-lowered-by-orbimed-advisors-llc.html.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.